These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12714902)

  • 1. [Nephroprotection in young type 1 diabetic patients treated with converting enzyme inhibitor].
    Benamar L; Laboudi A; Rhou H; Laouad I; Fahi Z; Bentata Y; Amar Y; Ezzaïtouni F; Ouzeddoun N; Bayahia R; Balafrej L; Touzani A; Benhamou B; Balafrej A; Guedira A
    Presse Med; 2003 Apr; 32(14):638-43. PubMed ID: 12714902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
    Ficociello LH; Perkins BA; Silva KH; Finkelstein DM; Ignatowska-Switalska H; Gaciong Z; Cupples LA; Aschengrau A; Warram JH; Krolewski AS
    Clin J Am Soc Nephrol; 2007 May; 2(3):461-9. PubMed ID: 17699452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotensin pathway?
    Mandal AK; Hiebert LM
    Clin Nephrol; 2008 Mar; 69(3):169-78. PubMed ID: 18397715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose angiotensin converting enzyme inhibitors: effect on renal function in normo- and hypertensive type 1 diabetic patients.
    Ciavarella A; Mustacchio A; Silletti A; Franchi R; Levorato M; Campieri C; Borgnino LC; Capozzi G; Morotti L; Vannini P
    Eur J Med; 1992 Sep; 1(5):268-72. PubMed ID: 1341608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy.
    Albayrak B; Cankaya E; Cetinkaya R; Cerrah S; Bilen Y
    Saudi J Kidney Dis Transpl; 2016 May; 27(3):512-8. PubMed ID: 27215243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
    Lewis JB; Berl T; Bain RP; Rohde RD; Lewis EJ
    Am J Kidney Dis; 1999 Nov; 34(5):809-17. PubMed ID: 10561135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.
    Wilmer WA; Hebert LA; Lewis EJ; Rohde RD; Whittier F; Cattran D; Levey AS; Lewis JB; Spitalewitz S; Blumenthal S; Bain RP
    Am J Kidney Dis; 1999 Aug; 34(2):308-14. PubMed ID: 10430979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.